Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS

被引：2
|
作者：
Murphy, Tracy
Leber, Brian
Bray, Mark R.
Chan, Steven M.
Gupta, Vikas
Khalaf, Dina
Maze, Dawn
McNamara, Caroline J.
Schimmer, Aaron D.
Schuh, Andre C.
Sibai, Hassan
Fletcher, Graham
Valiquette, Debbie
Martin, Kylie
Minden, Mark D.
Yee, Karen W. L.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-138822
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia
    Navada, Shyamala C.
    Fruchtman, Steven M.
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Petrone, Michael E.
    Zbyszewski, Patrick S.
    Holland, James F.
    Silverman, Lewis R.
    LEUKEMIA RESEARCH, 2018, 64 : 10 - 16
  • [2] HDAC Inhibitor Synergizes with GL-V9, a Derivative of Wogonin, to Suppress Acute Myeloid Leukemia By Downregulating ESPL1 and PLK4
    Yang, Chan
    Guo, Qinglong
    Hui, Hui
    Li, Hui
    Gu, Siyu
    Song, Chunhua
    Ge, Zheng
    BLOOD, 2023, 142
  • [3] FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
    Cortes, Jorge E.
    Watts, Justin
    Prebet, Thomas
    Schiller, Gary J.
    Lee, Sangmin
    Yang, Jay
    Wang, Eunice S.
    Dinner, Shira
    Ferrell, Paul Brent, Jr.
    Donnellan, Will
    Jonas, Brian A.
    Wei, Andrew H.
    Montesinos, Pau
    Sangerman, Montserrat Arnan
    Kelly, Patrick
    Li, Ping
    Sweeney, Jennifer
    Watson, Courtney
    Mohamed, Hesham
    Baer, Maria R.
    BLOOD, 2018, 132
  • [4] Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
    Bhatnagar, Bhavana
    Zhao, Qiuhong
    Mims, Alice S.
    Vasu, Sumithira
    Behbehani, Gregory K.
    Larkin, Karilyn
    Blachly, James S.
    Blum, William
    Klisovic, Rebecca B.
    Ruppert, Amy S.
    Orwick, Shelley
    Oakes, Christopher
    Ranganathan, Parvathi
    Byrd, John C.
    Walker, Alison R.
    Garzon, Ramiro
    LEUKEMIA & LYMPHOMA, 2020, 61 (02) : 387 - 396
  • [5] Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study
    Altman, Jessica K.
    Abaza, Yasmin
    Keng, Michael
    Maiti, Abhishek
    Koprivnikar, Jamie
    Tessler, Shoshi
    Blumberg, Chen
    Flaishon, Liat
    Ben Yakar, Ruth
    BLOOD, 2023, 142
  • [6] A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Zeidan, Amer M.
    Ridinger, Maya
    Lin, Tara L.
    Becker, Pamela S.
    Schiller, Gary J.
    Patel, Prapti A.
    Spira, Alexander I.
    Tsai, Michaela L.
    Samuelsz, Errin
    Silberman, Sandra L.
    Erlander, Mark
    Wang, Eunice S.
    CLINICAL CANCER RESEARCH, 2020, 26 (23) : 6132 - 6140
  • [7] PRELIMINARY RESULTS FROM A PHASE 1 STUDY EXAMINING THE NOVEL BCL-2 INHIBITOR S55746/BCL201 AS SINGLE AGENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC SYNDROME
    Wei, A.
    Bajel, A.
    Boissel, N.
    Kloos, I.
    Delifer, C.
    Banquet, S.
    Thomas, X.
    Vey, N.
    HAEMATOLOGICA, 2017, 102 : 373 - 373
  • [8] Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
    Mims, Alice S.
    Solh, Melhem
    Saultz, Jennifer N.
    Borate, Uma
    Pemmaraju, Naveen
    Borthakur, Gautam
    Roboz, Gail J.
    Powell, Ben
    Matusow, Bernice
    Halladay, Jason
    Vali, Shireen
    Hope, Chelsea L.
    Kundu, Madan G.
    Hsu, Ching
    Watkins, Paul
    Zhang, Chao
    Walling, Jackie M.
    Tsiatis, Athanasios C.
    DeZern, Amy E.
    BLOOD, 2021, 138
  • [9] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Borthakur, Gautum
    Cortes, Jorge
    Adam, Craig
    Ravandi, Farhad
    CANCER RESEARCH, 2014, 74 (19)
  • [10] Preliminary results of a phase II study of high dose lenalidomide as initial therapy for acute myeloid leukemia in patients ≥ 60 years old
    Fehniger, T. A.
    Nelson, A. D.
    Trinkaus, K.
    Abboud, C. N.
    Cashen, A. F.
    DiPersio, J. F.
    Ley, T. J.
    Uy, G. L.
    Westervelt, P.
    Vij, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345